LAUSR

In the past few decades, cancer immunotherapy has developed rapidly. Cancer immunotherapy, either used alone or in combination with a variety of immunotherapies (such as cancer therapeutic vaccines, adoptive cell therapy, or immune checkpoint blocking therapy), is a very attractive class of cancer therapy. However, so far, the clinical effect of most cancer immunotherapy is not satisfactory. It has been widely recognized that nanotechnology can enhance the efficacy of cancer immunotherapy. A variety of biogenic nanoparticles have been developed, which have excellent immunogenicity and modifiability, and can carry tumor therapeutic drugs to achieve combined therapy, so as to improve the effectiveness and durability of antitumor immunity while reducing adverse side effects. In this review, we summarized the key parameters and futures of three kinds of biogenic nanomaterials in cancer immunotherapy; we highlighted the progress of cancer immunotherapy based on outer membrane vesicles, virus-like particles, and exosomes. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Nanotechnology Approaches to Biology > Nanoscale Systems in Biology.